Luminex to acquire flow cytometry portfolio from MilliporeSigma

Luminex has signed a definitive agreement to acquire MilliporeSigma's flow cytometry portfolio for $75 million.

Luminex (Austin, TX) has signed a definitive agreement to acquire MilliporeSigma (Burlington, MA)'s flow cytometry portfolio for $75 million, consisting of approximately $69.9 million to be paid under a Stock and Asset Purchase Agreement and approximately $5.1 million in committed inventory purchases. The deal is expected to close by the end of 2018, and to contribute $40 million to $50 million in revenue to the company in 2019.

The acquisition expands Luminex's offering of flow-based detection systems, which is centered around its xMAP multiplexing technology that combines advanced fluidics, optics, and digital signal processing with its microsphere technology to deliver multiplexed assay capabilities.

MilliporeSigma's flow cytometry portfolio includes the Amnis imaging flow cytometry products for cell-based analysis, as well as the Guava high-performance systems based on microcapillary technologies.

For more information, please visit www.luminexcorp.com.

More in Biophotonics Techniques